Maziero Danilo, Azzam Gregory, de La Fuente Macarena, Stoyanova Radka, Ford John Chetley, Mellon Eric Albert
Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, 33136, United States.
Department of Radiation Medicine & Applied Sciences, UC San Diego Health, La Jolla, CA 92093, United States.
ArXiv. 2023 Apr 19:arXiv:2304.09128v2.
MRI-linear accelerator (MRI-Linac) systems allow for daily tracking of MRI changes during radiotherapy (RT). Since one common MRI-Linac operates at 0.35T, there are efforts towards developing protocols at that field strength. In this study we demonstrate the implementation of a post-contrast 3DT1-weighted (3DT1w) and dynamic contrast enhancement (DCE) protocol to assess glioblastoma response to RT using a 0.35T MRI-Linac.
The protocol implemented was used to acquire 3DT1w and DCE data from a flow phantom and two patients with glioblastoma (a responder and a non-responder) who underwent RT on a 0.35T-MRI-Linac. The detection of post-contrast enhanced volumes was evaluated by comparing the 3DT1w images from the 0.35T-MRI-Linac to images obtained using a 3T-standalone scanner. The DCE data were tested temporally and spatially using data from the flow phantom and patients. K maps were derived from DCE at three time points (a week before treatment-Pre RT, four weeks through treatment-Mid RT, and three weeks after treatment-Post RT) and were validated with patients' treatment outcomes.
The 3D-T1 contrast enhancement volumes were visually and volumetrically similar (±0.6-3.6%) between 0.35T MRI-Linac and 3T. DCE images showed temporal stability, and associated K maps were consistent with patient response to treatment. On average, K values showed a 54% decrease and 8.6% increase for a responder and non-responder respectively when Pre RT and Mid RT images were compared.
Our findings support the feasibility of obtaining post-contrast 3DT1w and DCE data from patients with glioblastoma using a 0.35T MRI-Linac system.
磁共振成像线性加速器(MRI-Linac)系统能够在放射治疗(RT)期间对MRI变化进行每日跟踪。由于一种常见的MRI-Linac工作在0.35T磁场强度,因此人们正在努力开发该场强下的方案。在本研究中,我们展示了一种使用0.35T MRI-Linac实施的对比剂增强后三维T1加权(3DT1w)和动态对比增强(DCE)方案,以评估胶质母细胞瘤对放疗的反应。
所实施的方案用于从一个流动模型以及两名接受0.35T MRI-Linac放疗的胶质母细胞瘤患者(一名有反应者和一名无反应者)获取3DT1w和DCE数据。通过将0.35T MRI-Linac的3DT1w图像与使用3T独立扫描仪获得的图像进行比较,评估对比剂增强后体积的检测情况。利用流动模型和患者的数据对DCE数据进行时间和空间测试。在三个时间点(治疗前一周 - 放疗前,治疗四周 - 放疗中期,治疗后三周 - 放疗后)从DCE得出K图,并与患者的治疗结果进行验证。
0.35T MRI-Linac和3T之间的三维T1对比增强体积在视觉和体积上相似(±0.6 - 3.6%)。DCE图像显示出时间稳定性,并且相关的K图与患者的治疗反应一致。当比较放疗前和放疗中期图像时,平均而言,有反应者和无反应者的K值分别下降了54%和增加了8.6%。
我们的研究结果支持使用0.35T MRI-Linac系统从胶质母细胞瘤患者获取对比剂增强后3DT1w和DCE数据的可行性。